About one-fourth of recurrent estrogen receptor-positive (ER+) breast cancers lose ER expression, which renders them resistant to endocrine therapy and able to grow uncontrolled. A team of researchers at Baylor College of Medicine has investigated how these cells lose their ER, and in the current study published in theProceedings of the National Academy of Sciences, they reveal a mechanism that not only explains the process but also offers possibilities to overcome it.

For years, our goal has been to tease out the complex puzzle of breast cancer progression to understand how the players interact with each other to confer resistance to therapy and persistent growth, said corresponding author Dr. Weei-Chin Lin, professor of medicine hematology and oncology and of molecular and cellular biology at Baylor. Our goal is to overcome this hurdle to restore ER receptor expression in these cancers so they become susceptible to therapy again, giving patients a better chance for recovery.

How breast cancer cells lose their ER

Two cellular proteins known as 14-3-3 and ER36 have been previously implicated in the development of breast cancer resistance to endocrine therapy.

Working with a mouse model of human ER+ breast cancer, we were surprised to find that over-expressing 14-3-3 in these tumors led to all the cancer cells becoming ER-negative (ER-), said Lin, a member of the Dan L Duncan Comprehensive Cancer Center. I still remember the day I saw the data. The change was dramatic all the tumors had lost their ER!

Studying the mechanism in animal models would be labor intensive, time consuming and expensive, so the researchers developed an alternative model. First author Lidija A. Wilhelms Garan, a student in Baylors Cancer and Cell Biology Graduate Program working in the Lin lab, developed a spheroid model of human breast cancer cells that mimics the progression from ER+ to ER- and provides a very useful experimental tool for future investigation.

In a patient, a breast tumor can take years to progress from ER+ to ER-, in our animal model it takes several months but in our spheroid model it switches from ER+ to ER- in 1 to 2 weeks, Garan said.

In the lab spheroid model the team found that once 14-3-3 is over-expressed in cancer cells under the right conditions, the cells will increase their levels of ER36 and this is followed by ER loss.

Other molecular players, such as AKT and GATA3, also are required, Garan said. Importantly, we also found that factors produced by the tumor microenvironment, which includes fibroblasts and immune cells that are part of the tumor mass and cross talk with the cancer cells, also are essential for the progression from ER+ to ER-.

We knew that 14-3-3, ER36, AKT and GATA3 were the key players involved in turning ER+ breast cancer cells into ER- cells. Here we have determined how they functionally interact with each other, laying out a map of the road that leads to ER loss, Lin said. I am very excited that with our spheroid breast cancer model we now have a valuable tool to study not only the cellular changes involved in breast cancer progression but also to test drugs for their ability to inhibit the process that leads to ER loss.

The protein 14-3-3 is overexpressed in about 60% of breast cancers. Not all patients that have high 14-3-3 will lose the ER, but for those who do, our findings may one day help restore their tumors to a therapy-sensitive state, Garan said. The translational aspect of this research has always been close to my heart to bring discoveries to the clinic and improve peoples lives.

Yang Xiao at Baylor College of Medicine also was an author of this work.

This work was supported by NIH Grants R01CA203824, R01CA100857, R21CA198041, T32GM136560 and T32CA174647 and Department of Defense Grants W81XWH-18-1-0329 and W81XWH-19-1-0369.

About one-fourth of recurrent estrogen receptor-positive (ER+) breast cancers lose ER expression, which renders them resistant to endocrine therapy and able to grow uncontrolled. A team of researchers at Baylor College of Medicine has investigated how these cells lose their ER, and in the current study published in the Proceedings of the National Academy of Sciences, they reveal a mechanism that not only explains the process but also offers possibilities to overcome it.

For years, our goal has been to tease out the complex puzzle of breast cancer progression to understand how the players interact with each other to confer resistance to therapy and persistent growth, said corresponding author Dr. Weei-Chin Lin, professor of medicine hematology and oncology and of molecular and cellular biology at Baylor. Our goal is to overcome this hurdle to restore ER receptor expression in these cancers so they become susceptible to therapy again, giving patients a better chance for recovery.

How breast cancer cells lose their ER

Two cellular proteins known as 14-3-3 and ER36 have been previously implicated in the development of breast cancer resistance to endocrine therapy.

Working with a mouse model of human ER+ breast cancer, we were surprised to find that over-expressing 14-3-3 in these tumors led to all the cancer cells becoming ER-negative (ER-), said Lin, a member of the Dan L Duncan Comprehensive Cancer Center. I still remember the day I saw the data. The change was dramatic all the tumors had lost their ER!

Studying the mechanism in animal models would be labor intensive, time consuming and expensive, so the researchers developed an alternative model. First author Lidija A. Wilhelms Garan, a student in Baylors Cancer and Cell Biology Graduate Program working in the Lin lab, developed a spheroid model of human breast cancer cells that mimics the progression from ER+ to ER- and provides a very useful experimental tool for future investigation.

In a patient, a breast tumor can take years to progress from ER+ to ER-, in our animal model it takes several months but in our spheroid model it switches from ER+ to ER- in 1 to 2 weeks, Garan said.

In the lab spheroid model the team found that once 14-3-3 is over-expressed in cancer cells under the right conditions, the cells will increase their levels of ER36 and this is followed by ER loss.

Other molecular players, such as AKT and GATA3, also are required, Garan said. Importantly, we also found that factors produced by the tumor microenvironment, which includes fibroblasts and immune cells that are part of the tumor mass and cross talk with the cancer cells, also are essential for the progression from ER+ to ER-.

We knew that 14-3-3, ER36, AKT and GATA3 were the key players involved in turning ER+ breast cancer cells into ER- cells. Here we have determined how they functionally interact with each other, laying out a map of the road that leads to ER loss, Lin said. I am very excited that with our spheroid breast cancer model we now have a valuable tool to study not only the cellular changes involved in breast cancer progression but also to test drugs for their ability to inhibit the process that leads to ER loss.

The protein 14-3-3 is overexpressed in about 60% of breast cancers. Not all patients that have high 14-3-3 will lose the ER, but for those who do, our findings may one day help restore their tumors to a therapy-sensitive state, Garan said. The translational aspect of this research has always been close to my heart to bring discoveries to the clinic and improve peoples lives.

Yang Xiao at Baylor College of Medicine also was an author of this work.

This work was supported by NIH Grants R01CA203824, R01CA100857, R21CA198041, T32GM136560 and T32CA174647 and Department of Defense Grants W81XWH-18-1-0329 and W81XWH-19-1-0369.

Proceedings of the National Academy of Sciences

Experimental study

Human tissue samples

14-3-3 drives estrogen receptor loss via ER36 induction and GATA3 inhibition in breast cancer

17-Oct-2022

Here is the original post:

Researchers uncover how breast cancer cells become resistant to therapy - EurekAlert

The health department of India's southern state Maharashtra has raised an alert over coronavirus (COVID-19) cases that may increase after the detection of new variants like BA.2.3.20 and BQ.1 reported from the state. For the first time, the variants have been detected in the country.

Health officials in the country are also concerned and have cautioned people as cases are expected to rise especially during the winter and the festive season.

The Maharashtra health department noted that the new XBB variant of coronavirus has a growth advantage over BA.2.75 and has immune evasive properties.

The bulletin said: "Some experts are predicting a rise in the coming winter season, especially in the festive environment. In WGS (whole genome sequencing), the proportion of BA.2.75 has decreased to 76 per cent from 95 per cent."

The variants are fueling cases globally. In some countries, including the United Kingdom, Germany and the United States, some are emerging as a strain responsible for maximum cases, especially BQ.1.

The US Centers for Disease Control and Prevention (CDC) noted that the BQ.1 and BQ.1.1 infections were currently 11 per cent of the country's caseloadacross the nation in the week ending October15.Less than a month ago, the pair were in just 1 per cent of cases. The steep rise is concerning the experts.

Watch this report:

Covid and its variants

When it comes to coronavirus variants, people have probably given up on keeping track of all the variants that are emerging now and then mostly the offspring of the Omicron variant. Notably, the variants are different in different parts of the world right now.

News outlet Fortune reported that the way Omicron variants are quickly growing globally is "unprecedented". The other feature concerning traits as some have improved immune evasion, increased transmissibility, or in some cases both.

As per the experts, the coronavirus could end up something like mild flu, or it might become bigger than what it is right now.

Dr Eric Topol, who is a professor of molecular medicine at Scripps Research and founder and director of the Scripps Research Translational Institute, told Fortune: "There have been times when different variants were on the move in different parts of the world, like the Gamma variant in South America, and Beta in South Africa."

"But this is different because now we have variants with extreme levels of immune evasion, and in any given country, potentially a few that could be in play at the same time," Dr Topol added.

Will it end up like flu?

It is vital that appropriate analysis is done timely to learn about the spread of variants as the fragmented cluster of Covid variants has been scattered around the globe.

Dr Ali Mokdad, a professor at the University of Washington's Institute for Health Metrics and Evaluation, told Fortune: "Many people globally are becoming susceptible all over again due to waning immunity from the vaccine and infections. People who have gotten Omicron BA.5 are susceptible five, six months later. Therefore anything circulating out there, theyre going to catch it."

According to Mokdad, the Covid virus will eventually become like the flu, which spear most during the winter season. In some years, the impact of the virus is worse than in others. He said that such a phenomenon with Covid could make it possible to target the virus with a single annual shot.

WATCH WION LIVE HERE

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

View post:

COVID-19: Multiple variants dominate the world. What will happen next? - WION

Biology solves a myriad of seemingly impossible physical challenges through the magic of active matter. Consider our lungs, for example. Using active-matter surfaces, they clear an astronomically large number of particulate contaminants that accompany each of the ten thousand liters of air we respire every day, ensuring that the lungs gas exchange surfaces remain functional.

Scientists and engineers are interested in active matter because it operates out of thermodynamic equilibrium, taking energy from its environment and using it to move or do work. That includesSho Takatori, an assistant professor of chemical engineering at UC Santa Barbara, who with his research group is working to achieve a deeper understanding of active matter, studying how it generates internal forces to control physical and chemical processes. That fundamental knowledge of the dynamics and unique properties of active matter may enable the design of synthetic materials with tunable properties, like the gas exchange and self-cleaning surfaces in our lungs.

Most engineered surfaces are designed to perform only a single task, like gas exchange or chemical catalysis. And they often have a chronic problem of surface contamination that clogs and deactivates the surface, explained Takatori. My lab envisions the development of multifunctional surfaces that enable the simultaneous operation of molecular sensing, recognition and catalysis. Active matter will play a central role in our mission.

In support of his leading-edge study of active matter, Takatori has received a prestigious Packard Fellowship for Science and Engineering from theDavid and Lucile Packard Foundation.

I am extremely honored and grateful to join this prestigious group of scientists and engineers as a Packard Fellow, said Takatori, who earned his Ph.D. in chemical engineering from the California Institute of Technology. Many scientists and engineers who I have respected and admired since I was a Ph.D. student have been Packard Fellows. Their accomplishments have inspired me to dream, which is why this fellowship is especially meaningful to me. The funding will also allow my lab to take creative approaches to high-risk, high-reward projects.

Takatori is one of only twenty early-career scientists and engineers from across the country who were named tothis years class of Packard Fellows, who each receives $875,000 over five years to take creative approaches to their research, dare to think big and follow new ideas wherever they lead. Since its creation in 1988, the Packard Foundation has awarded nearly $500 million to support more than 680 scientists and engineers. Packard Fellows have gone on to receive major awards and recognitions, including Nobel Prizes, Fields Medals and elections to the National Academies of Engineering, of Sciences, and of Medicine.

The College of Engineering is tremendously proud of Professor Takatori for receiving a Packard Fellowship, the largest non-governmental fellowship and one of the most prestigious early-career awards, saidTresa Pollock,the interim dean of the College of Engineering and Alcoa Distinguished Professor of Materials. He has already established himself as a leader in the fields of active matter and cell membrane engineering, and this recognition allows him to push the boundaries of discovery even further to improve our quality of life.

In his project, Takatori seeks to use basic active-matter components mechanical motor, driven constituent and energy source to engineer synthetic surfaces that actuate multifunctional properties.

Our goal is to direct the flow of matter by orchestrating these living molecules found within biological systems, guided by new fluid mechanics models and advanced computations, said Takatori.

In order to transform their vision into reality, his group must overcome key obstacles in the fields of fluid mechanics and surface science, which is the study of the physical and chemical phenomena that occur at the interface of two phases. A major goal is generating surface flows in the absence of any externally imposed force, a grand challenge in fluid mechanics. In most systems, like water flowing through a pipe, an externally imposed pressure drop is required to create flow and movement in the system. Takatori wants to createinternalforces to actuate surface flows by directing active matter, which can be used to control the transport of molecules on surfaces. Possible applications for such a technology include sensors that can detect the presence of molecular species in the fluid, surfaces that instinctively self-assemble in a specific geometry and catalytic surfaces that increase the rate of chemical reactions in the system.

Our new theoretical framework is the key enabling breakthrough that will allow us to predict and design nonequilibrium active matter, said Takatori. This is significant because existing textbook theories often fail to predict the behavior of materials driven out of equilibrium, like batteries, biological tissues and other systems that dynamically change with time and/or space. Active matter serves as a good model system to advance new theories that may be applied to a variety of chemical and physical systems.

Takatori said that his research group possesses the ability to complete this project by combining theory, simulation and experiments to control and design active-matter surfaces with desired properties.

The successful realization of this technology would generate tunable, living surfaces that combine the dynamic programmability of active matter and the molecular specificity of biological membranes, he said. Our hope is that this project will lead to the design of multifunctional surfaces that can perform sensing and communication in ways that have never been achieved.

Takatori is the fourth Packard Fellow among the chemical engineering departments eighteen faculty members an indication, he said, of the high-quality research and teaching that takes place within the department and across the university.

Packard Fellows are dared to think big, explore new frontiers and follow uncharted paths that may lead to groundbreaking discoveries, said Takatori. The fact that more than 20% of our faculty are recipients is one of the many testaments to the creative science and engineering that the faculty direct. It also displays the strength and innovativeness of our departments exceptionally talented students and postdoctoral researchers who take off with exciting, out-of-the-box ideas.

We are thrilled that the David and Lucile Packard Foundation recognizes and supports the high-impact potential of Professor Takatoris research, saidRachel Segalman,chair of chemical engineering. This award affords him the opportunity to take risks in pursuit of scientific breakthroughs that would improve peoples lives and revolutionize everything from medicine to robotics.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original:

The magic of active matter - EurekAlert

Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts

San Diego, California and London, UK, October 17, 2022 Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy.

The newly formed SAB will provide input into Replays strategy, portfolio of next-generation genomic and cell therapy medicines, and associated technology platforms. The SAB complements Replays industry seasoned management team and board.

Adrian Woolfson, Executive Chairman, President and Co-founder of Replay, commented: The multi-disciplinary nature of our scientific advisory board reflects Replays commitment to invoking innovation from a broad range of scientific specialties and leveraging this across our research and development programs. Our new advisors represent some of the best scientific minds of their generation and bring a unique and differentiated portfolio of expertise into the Company. Their contribution to Replay will be invaluable as we continue to address some of the most significant challenges in genomic medicine and cell therapy.

Lachlan MacKinnon, Chief Executive Officer and Co-founder of Replay, added: Following on from our recent launch, the formation of our uniquely distinguished scientific advisory board further demonstrates Replays commitment to developing a cutting-edge portfolio of medicines guided by world-class science. The combined inter-disciplinary expertise of our scientific advisory board brings tremendous knowledge and experience into the Company as we continue to expand our operations, with a view to developing transformative genomic medicines.

Replays SAB will be chaired by Professor Roger Kornberg, PhD, a biochemist whose laboratory work has focused on the molecular basis of eukaryotic transcription and in particular the structure of RNA polymerase and the nucleosome.

Professor Roger Kornberg, PhD, Chairman of Replays Scientific Advisory Board, said: Replays scientific advisory board incorporates expertise across several areas relevant to Replays genomic medicine and cell therapy technology platforms. I am excited to be working with this exceptional group of scientists and believe we can make a compelling contribution and help Replay realize its vision for genomic medicine.

Replays SAB members are as follows:

Professor Roger D. Kornberg PhD (Chairman), is the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University School of Medicine. He was awarded the Nobel Prize in Chemistry (2006).

Professor Carl H. June, MD, is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of Translational Research at the Abramson Cancer Center. He was the co-founder of TMunity.

Professor Robert S. Langer, ScD, FREng,is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT), co-founder of Moderna, and was formerly Chair of the FDAs Science Board. He has been awarded 40 honorary doctorates, written over 1,500 articles, and received over 220 awards.

Professor Lynne E. Maquat, PhD, is the J. Lowell Orbinson Endowed Chair and Professor of Biochemistry and Biophysics, University of Rochester Medical Center, and founding Director of the Center for RNA Biology, University of Rochester, Rochester NY. She was awarded the Wolf Prize in Medicine from Israel (2021) and the Warren Alpert Foundation Prize from Harvard Medical School (2021).

Professor Dame Carol Robinson, DBE FRS FMedSci FRSC, is the Dr Lees Professor of Physical and Theoretical Chemistry, the Founding Director of the Kavli Institute for Nanoscience Discovery at Oxford, and a Founder of OMass Therapeutics. She is a Professorial Fellow at Exeter College, Oxford, and was formerly President of the Royal Society of Chemistry.

Professor David V. Schaffer, PhD, is the Hubbard Howe Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at the University of California, Berkeley, where he is Director of theBakar BioEnginuity Hub and Director of the California Institute for Quantitative Biosciences (QB3). He was the co-founder of 4D Molecular Therapeutics, Ignite Immunotherapies, Rewrite, and 5 additional companies.

Professor Stuart L. Schreiber, PhD, is the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University. He is a co-founder of the Broad Institute at Harvard University and MIT and co-founder of Harvards Institute of Chemistry and Cell Biology. He was awarded the Wolf Prize in Chemistry (2016).

Professor Pamela Silver, PhD, is the Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology in the Department of Systems Biology at Harvard Medical School, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.

Professor Sir John E. Walker, FRS FMedSci, is Emeritus Director and Professor at the MRC Mitochondrial Biology Unit at the University of Cambridge, England, and a fellow of Sidney Sussex College, Cambridge. He was awarded the Nobel Prize in Chemistry (1997).

Professor John Fraser Wright, PhD, is Professor of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, and Director of Technology Innovation at the Center for Definitive and Curative Medicine at Stanford University. He is co-founder and was Chief Technology Officer at Spark Therapeutics and is co-founder and Chief Scientific Advisor at Kriya Therapeutics.

Ends

About Replay

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realizing its full potential. The Companys hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies that leverage its technology platforms. For example, Replays synHSV technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replays four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company that leverages its evolutionary inference machine learning and genome writing technology to optimize enzyme functionality. Replay is led by a world-class team of academics, entrepreneurs, and industry experts.

The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.

Replay is headquartered in San Diego, California, and London, UK. For further information please visit http://www.replay.bio and follow us on LinkedIn and Twitter.

Contacts:

Replay

Dr Adrian Woolfson/Lachlan MacKinnon

info@replay.bio

Consilium Strategic Communications Media relations

Amber Fennell/Tracy Cheung/Andrew Stern

replay@consilium-comms.com

Originally posted here:

Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - GlobeNewswire

Committed to exploring new frontiers in basic and translational research.

The Department of Biochemistry and Molecular Genetics is an integral part of the vibrant biomedical research community at the University of Alabama at Birmingham (UAB). UAB ranks among the top public institutions of higher education in terms of research and training awards. Research conducted by the faculty, staff, and students of the Department of Biochemistry and Molecular Genetics is currently supported by more than $7.1 million per year in extramural, investigator-initiated grants.

The Department of Biochemistry and Molecular Genetics carries out cutting-edge basic and translational research. Research strengths in the department includes cancer biology, chromatin and epigenetic signaling, metabolism and signaling, regulation of gene expression, structural biology, DNA synthesis and repair, and disease mechanisms.

Graduate students and postdoctoral fellows in the Department of Biochemistry and Molecular Genetics are trained to carry out hypothesis-driven research using advanced research techniques. This training will prepare our graduates for a career in not just biomedical research, but also in other diverse fields that require critical thinking. Our faculty also proudly trains professional (MD, DDS, & DO) students, as well as undergraduate students at UAB.

View post:

School of Medicine - Biochemistry and Molecular Genetics | UAB

The English-language Master's degree programme in Molecular Medicine is directed at highly motivated students from home and abroad who are interested in the subject. The prerequisite is a Bachelor's degree with a focus on either natural sciences or molecular medicine. The degree programme will provide deeper knowledge of topics relating to molecular medicine and clinical theory such as immunology, oncology, genetics, pharmacology and cell biology. In addition, there are also three laboratory internships, each lasting eight weeks. A Master's thesis will be written within six months.

Name of program: Molecular MedicineDegree: Master of Science (M.Sc.)Length of program: 3 semestersProgram start: winter semester onlyApplication deadline: May 30th for winter semester 2021/22 Prerequisites: B.Sc. in Molecular Medicine or a related fieldAdmissions: limited spaces available (apply directly through faculty)Language requirements: English (certification mandatory)

A proof of measles protection is required for enrollment. The form must be completed by your primary care physician.

If necessary, please use the time between your application and enrollment to get vaccinated or to refresh your vaccination status. The short period of time for acceptance after admission is usually not sufficient for this.

For inquiries, please contact the Office of the Dean of Medical Studies studiendekanat@med.uni-goettingen.de.

Program OverviewThe eighteen-month Masters program in Molecular Medicine expands upon the scientific and medical knowledge basis acquired in Bachelor programs and explores in depth the molecular aspects of medicine. Its goal is to train students thoroughly in an area of application of molecular medicine. It should enable students to engage in independent and creative research at the crossroads of medicine and basic science.

Program StructureDuring the first year, students attend the course ?Molecular-pathological aspects of organ systems?, which is designed to heighten their understanding of the interaction between clinical and molecular science. In other obligatory module courses particular aspects of molecular immunology, bacteriology, human genetics and oncology are treated. The final six months are to be devoted to work on a master?s thesis.

A graduate of the Master?s program in Molecular Medicine should have solid knowledge of the methods of scientific research as well as be able to apply a wide spectrum of molecular-medical methods to provide concrete solutions to scientific problems.

Our graduates secure positions in all areas of medical research, laboratory diagnostics, and medical biotechnology, in both the academic and the commercial sectors. Places of employment include: clinics (molecular and biochemical diagnostics, clinical research, etc.); government agencies (criminal investigation offices, public health departments, commercial regulatory authorities, environmental protection agencies, medical associations); places of academic research (universities, Max Planck Institutes and other large research institutions); industrial settings (biomedical technology, production and quality control, basic research and development, publishing, marketing, administration); private laboratories (molecular diagnostics and analysis, environmental protection); and other institutions (ministries, research advancement organizations, technology transfer facilities).

See the rest here:

Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen

Medical students around the country start their journey to become physicians by studying the human body in gross anatomy labs, where they are reminded that real people volunteered their bodies to serve as educational tools to train them to help others.

Its no different at the University of Arizona Colleges of Medicine Tucson and Phoenix. The Tucson-based Willed Body Program annually accepts 150-200 whole body donations, which are embalmed and put in cold storage for use by both colleges for up to two years. Afterward, the remains are cremated and ashes returned to the families or spread in nearby mountains.

The people of Arizona are incredibly generous in this respect, because I know some willed body programs do have issues with not enough donors. And we never do, said Jean Wilson, PhD, program director, anatomy instructor, professor of cellular and molecular medicine, and BIO5 Institute member. We always have enough every year to supply the needs of the college and beyond.

The Willed Body Program serves more than just the Colleges of Medicine Tucson and Phoenix. It also supplies bodies for the A.T. Still University School of Osteopathic Medicine in Phoenix and nursing programs at the UArizona College of Nursing, Arizona State University and Northern Arizona University.

Currently, about 9,000 Arizonans have been issued willed body donor cards through the program that was founded in 1967.

Dr. Wilson credits the programs success in large part to the respectful, professional tone set by its funeral directors, Jared and Kat Alvarado. The husband-and-wife team work with donors, the families, faculty, physicians, nurses, students and others who benefit from the program.

Theyre unbelievable, Dr. Wilson said of the Alvarados. In the 32 years Ive been affiliated with the program, weve had people who are fine. But between the two of them, Kat and Jared are exceptional. Theyre so good with the donor families and the donors. They know exactly the right things to say. Theyre very gentle and empathetic. We are super lucky to have them.

Jared has been with the program 12 years, and Kat for seven. Both hold associates degrees in mortuary science and served three-year apprenticeships before being licensed as morticians.

Ive worked at places without an in-house willed body program, where you deal with a third party, said James Proffitt, PhD, College of Medicine Tucson lead instructor for the gross anatomy lab and cellular and molecular medicine assistant professor. Having two trained funeral directors and morticians people who really understand the process of grief and dying makes this so much more community oriented, humanistic, engaging and empathetic with what donors and students need.

I take the same approach as if I were at a funeral home, but feelings surrounding death are slightly less intense. The donors who participate in the Willed Body Program want to be here and most express their excitement at being able to contribute to medical education.Kat Alvarado, UArizona Willed Body Program funeral director, embalmer and coordinator

The donor families are very used to working with Kat and Jared, Dr. Proffitt said. They understand their best interests are looked out for by those two. It creates this kind of community, this family of donors. And this is something I try to impress on our students. These donors arent people from somewhere else. Theyre Arizonans. Theyre our neighbors.

Kat said her interest in the field was piqued in college, when she worked as a funeral home service attendant. She later served as an embalmer, cremationist and funeral director for a funeral home.

At UArizona, she said, I take the same approach as if I were at a funeral home, but feelings surrounding death are slightly less intense. The donors who participate in the Willed Body Program want to be here and most express their excitement at being able to contribute to medical education.

Unlike his wife, Jared said he sort of fell into his career as a funeral director.

After he graduated from high school, he took a job answering the phone at a funeral home. He started working with decedents his second day on the job. He went to mortuary school in Dallas, apprenticed in Texas and Arizona, and served as a crematory operator and embalmer before joining the Willed Body Program.

Death is hard on the families. But, at the same time, its great to hear how proud they are of their loved one donating their body to students for education, Jared said of what families say when he and Kat pick up a donated body. They hear similar comments at an annual willed body ceremony that offers donor families a chance to honor their loved ones.

Nearly 400 people attended the Willed Body Memorial Service in March. Among the speakers were the Alvarados, Dr. Wilson and medical students who expressed their gratitude for the donors beautiful and lasting gift to help them better learn their craft.

Jared does outreach to local high schools, talking to students about his experiences while encouraging others to follow in his footsteps.

My outreach to youth is important to me, he said. I wish I had someone who came to my high school to speak about these types of professions. Its my way of helping out as best I can.

The Alvarados are more than morticians. They also help fulfill continuing education needs for faculty physicians and nurses. In 2015, Jared Alvarado won the College of Medicine Tucsons Appointed Personnel Lura Hanekamp Award of Excellence for the part he plays in education for students, physicians and health professionals.

In 2019, Kat won a UArizona Individual Award for Excellence for her dedication to handling the programs administrative needs as Willed Body Program coordinator.

Jared also helps write academic papers related to the program, including a 2019 article on donor bodies used for students teaching students as a novel solution to time demands on doctors.

The program also hosts training opportunities for other medical professionals where staff need to understand human anatomy, including paramedics, emergency medical technicians and military health personnel. Jared assists in some training, including non-UArizona instruction for Davis-Monthan Air Force Base staff.

It usually is just myself and their instructors, so Im able to show them techniques and things Ive learned as part of the College of Medicine, he said.

Both are on call 24/7 to ensure the Willed Body Programs ongoing success, whether that involves working with instructors to help design specific training or traveling across the state to pick up donor bodies from a family or funeral home.

Thats important, Dr. Proffitt said, because donors bodies are the canvas upon which students and trainees learn to practice their art as healers. Without them, there is no healers art.

More:

Married Couple are 'Heart and Soul' of Willed Body Program - University of Arizona

Wilmington, Delaware, United States, Transparency Market Research Inc.: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that involves the chronic inflammation of the colon or large intestine. It causes ulcers (sores) and long-lasting inflammation in the digestive tract and typically affects the innermost lining of the colon and rectum. The symptoms of the condition include dehydration, pus or blood in diarrhea, belly pain, fever, and urgent and painful bowel movements. Though the exact cause of the condition has not been identified, abnormal activation of the immune system in an individuals intestines leads to ulceration portions and chronic inflammation of the colon.

Read Report Overview - https://www.transparencymarketresearch.com/ulcerative-colitis-treatment-market.html

Ulcerative colitis can be classified into ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis, or universal colitis and fulminant colitis according to the degree of inflammation and its location. Inflammation in ulcerative proctitis is limited to the rectum. In proctosigmoiditis, inflammation is observed in the sigmoid colon and rectum. Inflammation from the rectum extending to the left colon takes place in left-sided colitis. In universal colitis or pancolitis, inflammation affects the entire colon. Fulminant colitis is a severe but rare form of universal colitis.

Rise in number of patients with ulcerative colitis globally is a prominent factor driving the expansion of the ulcerative colitis treatment market. According to a report published in the Crohns & Colitis Foundation of America (CCFA), around 1.6 million people in the U.S were affected with IBD in 2014, with 70,000 new cases reported each year. Of the total number of people with IBD in the U.S, 907,000 had ulcerative colitis.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47604

The number of new cases of UC are reportedly rising rapidly in newly industrialized countries in Eastern Europe, South America, Africa, and Asia. Increase in use of antibiotics, westernized dietary patterns, rise in exposure to pollution, and improvement in hygiene are some of the factors playing a pivotal role in the increased incidence of UC in developing countries as compared to developed countries. The highest increase in the incidence of these conditions has been reported in countries such as Japan, India, China, etc.

New collaborations and partnerships between biopharmaceutical companies is also helping in providing novel treatment options for the management of UC. In February 2018, Cook Biotech Inc. entered into a new partnership with Regentys in order to develop a new treatment for UC. As per the agreement, Cook Biotech will develop and produce Regentys ECMH Rectal Solution (extracellular matrix hydrogel), a patented and non-surgical hydrogel therapy for patients suffering from ulcerative colitis. In December 2017, Roche announced a collaborative agreement with Boehringer Ingelheim for the discovery and manufacture of novel LNA (locked nucleic acid) oligonucleotides used in the management of inflammatory bowel diseases such as UC.

Get COVID-19 Analysis on Ulcerative Colitis (UC) Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=47604

The global ulcerative colitis treatment market can be segmented based on treatment, end-user, and geography. In terms of treatment, the ulcerative colitis treatment market can be divided into

non-surgical and surgical. The non-surgical segment can be further classified into 5-aminosalicylic acid, corticosteroids, immunosuppressants, and others. Based on end-user, the ulcerative colitis treatment market can be divided into hospitals, ambulatory surgical centers, and clinics.

In terms of geography, the global ulcerative colitis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global ulcerative colitis treatment market due to a sizeable population with UC along with continued funding for development of new therapeutics for the treatment of the condition.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=47604

North America is followed by Europe. Infusion of fresh capital by private investment firms in companies involved in the research of innovative treatment methods for UC is likely to propel the ulcerative colitis treatment market in Europe. In May 2018, Sublimity Therapeutics Limited, a specialty pharmaceutical company, announced that it had successfully raised US$ 64 Mn from investment firms led by Longitude Capital, OrbiMed, and HBM Healthcare Investments. The proceeds from the capital raised will be used for the clinical development of STI-0529 for the treatment of moderate to severe UC.

Prominent players operating in the global ulcerative colitis treatment market are Boehringer Ingelheim, Cook Biotech Inc., Pfizer, Inc, Regentys, and Sublimity Therapeutics Limited.

More Trending Reports by Transparency Market Research

Nanomedicine Market: Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Smart Medical Devices Market: Smart Medical Devices Market (Product Type: Diagnostic & Monitoring Devices, Therapeutic Devices, Injury Prevention & Rehabilitation Devices, and Others; Modality: Portable, Wearable, and Others; and End-user: Hospitals, Clinics, Home Care Settings, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Bioinformatics Market: Bioinformatics Market (Platforms, Tools, and Services: Platforms, Tools, and Services; and Application: Preventive Medicine, Molecular Medicine, Gene Therapy, Drug Development, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Taurine Market: Taurine Market (Type: Food Grade and Pharmaceutical Grade; Application: Health Care Products, Pet Food, Beverage, and Others; and Form: Tablets/Capsules, Liquid-based Serum, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Telehealth Market: Telehealth Market (Component: Hardware, Software, and Services; Application: Radiology, Cardiology, Urgent Care, Remote ICU, Psychiatry, Dermatology, and Others; and End-user: Payers, Providers, Patients, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Medical Device Technologies Market: Medical Device Technologies Market (Device Type: Cardiology Devices, Diagnostic Imaging Devices, Orthopedic Devices, Ophthalmology Devices, Endoscopy Devices, Diabetes Care Devices, Wound Management Devices, Kidney/Dialysis Devices, Anesthesia & Respiratory Care Devices, and Others; and End-user: Academics & Research, Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Animal Healthcare Market: Animal Healthcare Market (Product Type: Pharmaceuticals, Feed Additives, and Vaccines; and Animal Type: Companion Animals and Production Animals) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Erectile Dysfunction Drugs Market: Erectile Dysfunction (ED) Drugs Market (Drug: Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Read the original post:

Ulcerative Colitis (UC) Treatment Market: Rise in Number of Patients with Ulcerative Colitis Globally to Drive the Market - BioSpace

Caris Life Sciences announced this week that it will be broadening its partnership with Epic, integrating its molecular testing portfolio with Epic's Orders and Results Anywhere network.

WHY IT MATTERSCaris offers whole exome and whole transcriptome sequencing, and by applying AI modeling to its clinico-genomic database, it can help researchers gain better insights into the molecular complexity of disease.

The new project builds on the existing integration of Caris' Genomics Module within Epicand will expand capabilities by offering easier ordering and receipt of molecular profiling results directly in patients' electronic health records.

Officials say Caris' whole suite of molecular profile services for tissue and blood samples will be available within the Orders and Results Anywhere network.

ORA network integration, expected to be available later this year, will help drive data-driven decision-making for Epic customers which represent 60% of oncologists nationwide, the companies note. By putting ordering and results directly into the network, Caris says it aims to offer more streamlined access to structured genomic data within the Epic environment.

THE LARGER TRENDThis is just the most recent in a string of announcements involving Epic and precision medicine technology developers. In June, Myriad Genetics announced it was working to integrate its genetic testing services within Epic's EHR workflows offering providers genetic insights for more personalized care and giving patients easier access to test results within MyChart.

In April, Guardant Health, which develops precision oncology tools,announced its own collaboration with Epic to streamline clinicians' ability to order Guardant blood tests, liquid biopsies and more within the EHR.

And this past August, Foundation Medicine announced a deal with Epic toadd its genomic profiling and testing services to the EHR workflow.

In other Epic news, the vendor announced this past month that it would join the Trusted Exchange Framework and Common Agreement and apply to connect to TEFCA as an inaugural Qualified Health Information Network.

ON THE RECORD"Caris Life Sciences is committed to fulfilling our organizational promise of making personalized precision medicine accessible to as many physicians and patients as possible," David Spetzler, president and CEO of Caris, said in a statement. "Building on the success of our Epic Genomics Module integration, ORA will further enhance patient access to critical molecular results they need to fight, and hopefully beat, cancer."

Alan Hutchison, VP of population health at Epic, said, "We are excited for this enhanced partnership with Caris to further increase health access and care, and the opportunity to help deliver precision medicine to a greater number of communities."

Twitter:@MikeMiliardHITNEmail the writer:mike.miliard@himssmedia.comHealthcare IT News is a HIMSS publication.

Original post:

Epic, Caris Life Sciences working together on molecular testing integration - Healthcare IT News

(Precision Vaccinations)

As of early July 2022, uncertainty persists as SARS-CoV-2 coronavirus mutations continue emerging. According to the World Health Organization, the Omicron BA.x variants are now dominant worldwide.

There is a clear need for strategies to tackle emerging variants and protect populations against potential future threats to human health, says vaccine researchers from the University of Oxford and Caltech.

A new consortium announced on June 5, 2022, aims to address these issues by establishing the first-in-human clinical proof of concept for a new vaccine design.

The consortium brings together researchers from the University of Oxford and Caltech to collaborate with deep tech innovation organization CPI and industrial biotechnology company Ingenza Ltd (Caltech-CPI-Oxford-Ingenza).

The Coalition for Epidemic Preparedness Innovations (CEPI) will partner with the consortium and has announced up to US $30 million to fund pre-clinical studies, GMP manufacturing, and Phase 1 trial based on this technology.

The vaccine will target both SARS-CoV-2 and several related bat viruses which have the potential to spread to humans. It builds on technologies developed by the Molecular Immunology Group at the University of Oxford and by the Bjorkman Group based at Caltech led by Professor Alain Townsend at the MRC Human Immunology Unit and Professor Pamela Bjorkman, respectively.

In contrast to many existing vaccine designs that use mRNA or a viral vector to present sections of the spike protein of a single type of virus to the immune system, this new vaccine will use protein nanoparticles containing a protein glue to attach related antigenic sections of the spike proteins from eight different viruses. By incorporating a mosaic-8 vaccine design created at Caltech, these nanoparticles would favor immune responses to the shared parts of each type of coronaviruses within a single vaccine.

Evidence published today in Science by the researchers demonstrates that this vaccine technology elicits protective immune responses against SARS-like viruses but also against some coronaviruses not presented in the trial vaccine. This suggests that the technology could protect against future novel SARS-CoV-2 variants and as-yet-undiscovered coronaviruses with the potential to spill over from animal populations.

Alain Townsend, Oxford Lead of the consortium, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, said:

The evolution of this consortium is an example of collaborative science at its best. We had been deeply impressed by the power of the glue for sticking proteins together developed by Mark Howarth (Biochemistry Oxford) and derived from his beautiful basic science investigations of the Streptococcus pyogenes bacterium.'

Together, we used this technology to make a prototype nanoparticle SARS-CoV-2 vaccine that induced highly potent responses in preclinical studies.'

Through connections made by Ian Wilkinson (Absolute Antibody), we joined with colleagues at Ingenza and CPI who succeeded in making a fully functional version of the vaccine produced in microbes, thus reducing the cost of production. In addition, we have been collaborating with Prof. Pamela Bjorkman and the Caltech team, who had independently developed the brilliant concept of the mosaic version of the vaccine and are excited to continue working with this world-class consortium.

The consortium partners are committed to equitable access to the project's outputs.

Dr. Jack Tan, Project Manager (Oxford) of the consortium, Senior Postdoctoral Scientist at the MRC Weatherall Institute of Molecular Medicine, said:

We are delighted to work with CEPI to further this nanoparticle technology to produce efficacious, low-cost, infrastructure-independent vaccine that will be accessible to low- and middle-income countries.

Dr. Richard Hatchett, CEO of CEPI, commented in a press release issued on July 6, 2022, There have already been three serious coronavirus epidemics or pandemics in the 21st century and COVID-19 continues to have a devastating impact on the worlds health, society, and economy. Creating vaccines that could provide broad protection against emerging COVID-19 variants and future coronavirus threats would not only help mitigate the damaging effects of another COVID-19-like pandemic, but it could also help reduce the time taken and funding spent continually updating vaccine formulations.

Thats why we are delighted to partner with this CPI-led research consortium to build on Wellcome Leaps initial investment to further advance this pioneering mosaic nanoparticle vaccine technology that, if successful, could work towards consigning the threat posed by coronaviruses to the history books.

The consortium aims to commence a Phase 1 trial in 2024, led by the Oxford Vaccine Group.

PrecisionVaccinationspublishes fact-checked, research-based news curated for mobile readership.

The rest is here:

$30 Million Funding Empowers All-in-One Vaccine Candidate to Tackle Future Coronaviruses - Precision Vaccinations

Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, testified before a Senate hearing in June.Credit...Haiyun Jiang The New York Times

As the coronavirus pandemic entered its third year, the American public had lost much of its trust both in public health experts and in government leaders, and was less worried than before about Covid-19, according to a survey conducted in early May and released Thursday by the Pew Research Center.

Confidence ratings for public health officials, like those at the Centers for Disease Control and Prevention; for state and local elected officials; and for President Biden fell in a range from 43 percent to 54 percent in the survey much lower than during the early stages of the pandemic.

The survey found a wide partisan gap in attitudes. Overall, 52 percent of respondents said that public health officials had done an excellent or good job at managing the pandemic. But while 72 percent of Democrats in the survey said they felt that way, only 29 percent of Republicans did.

Democrats were also more likely than Republicans 67 percent to 51 percent to say they had at least some confidence in how prepared the nations health care system was to address a future global health emergency.

Dr. Yvonne Maldonado, a pediatric infectious disease physician at Stanford Medicine who chairs the American Academy of Pediatrics committee on infectious diseases, said the pandemic only widened the countrys partisan divide over those issues.

I think that mistrust in government and politicians, and even to a certain extent science, started well before the pandemic, and it just was exacerbated, Dr. Maldonado said.

Pandemic fatigue and a growing notion that Covid is now a part of everyday life probably played a role in the changing public attitudes identified in the Pew survey, according to Dr. Robert Wachter, a professor and the chair of the medicine department at the University of California, San Francisco.

I think peoples thinking is very much influenced by the fact that the chances youre going to die of Covid have gone down substantially on a per-case basis, Dr. Wachter said.

Public confidence in medical centers and hospitals remained high: Eight out of ten respondents said those institutions were continuing to manage the pandemic well, a small decline from 88 percent two years ago.

The survey found that Americans have grown less worried about catching the virus or unintentionally spreading it to others. Most respondents said they thought the worst of the pandemic was over, and only about a quarter saw the coronavirus as a significant threat to their personal health, down from 30 percent in January.

The average number of new confirmed cases reported daily across the United States surged to record highs in January, driven by the Omicron variant. The surge receded swiftly as the winter ended, but the average started to rise again in the spring. In recent weeks since the survey was taken, the number of new confirmed cases has been around 100,000 a day, according to a New York Times database.

Those figures are thought to understate the true number of infections, however, because of increasing reliance on at-home testing, the closings of mass testing sites and reduced frequency in data reporting by states. New deaths have fallen significantly since the winter surge, and Covid now kills fewer than 400 people daily in the United States.

Though many people are still becoming infected, survey data shows that public concern about the virus has declined substantially. The Pew survey found that 76 percent of respondents in May thought the worst of the pandemic was over, compared with about half in January.

Thats the first time during the entire outbreak that weve had a majority of Americans saying this, said Alec Tyson, an associate director of research at the Pew Research Center and a lead author of the survey.

A narrow majority of respondents in the latest survey 55 percent said they thought vaccination had been somewhat or very effective at curbing the spread of the coronavirus. About half felt that way about wearing masks indoors. Respondents were more skeptical about the efficacy of people staying at least six feet apart indoors, with only 34 percent considering that practice at least somewhat effective.

The survey found very wide partisan gaps in attitudes toward all those preventive measures, especially mask-wearing, with Republicans far more likely than Democrats to say they did little or no good.

The poll included 10,282 adults who were surveyed online between May 2 and May 8.

Read more from the original source:

The pandemic has eroded Americans' trust in experts and elected leaders alike, a survey finds. - The New York Times

Newswise A multi-disciplinary, One Health approach to cancer research is necessary to guide society in reduction of toxic substances, as well as regulation of chemical impacts on the environment and public health, according to an editorial published recently in Issue II of Annals of Research in Oncology.

This medical-scientific journal is published by Editor in Chief Professor Antonio Giordano, M.D., Ph.D., Director and Founder of Sbarro Institute for Cancer Research and Molecular Medicine, and the Sbarro Health Research Organization (SHRO), at Temple University. The editorial by Prof. Philip Landrigan, Director of the Global Public Health Programme, highlights the relationship between environmental issues and childhood cancer cases, which have been growing rapidly over the past 50 years.

Landrigan's editorial moves towards the new scientific paradigm known as One Health, by which is meant the indissoluble intertwining of three factors: human health, animal health and environmental health as interconnected and dependent on each other.

In particular, Landrigan emphasises the link between environment and cancer in paediatric subjects, underlining the lack of scientific models that consider the use of chemicals with undesirable effects on human health, which are not carefully studied, and the consequent increase in oncological cases in paediatrics. In fact, there is evidence that environmental exposure, in particular to manufactured chemicals, are a major cause of childhood cancer. The National Cancer Institute currently directs about 1% of its funding towards research into environmental causes of paediatric cancers.

Landrigan's hope is to identify new scientific models based on epidemiological and toxicological studies to address the rising incidence of childhood cancer, a major challenge for society and the cancer and public health communities.

Excerpt from:

One Health Approach Is Necessary to Address Rising Environmental Causes of Childhood Cancers - Newswise

STOCKHOLM, July 7, 2022 /PRNewswire/ --The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamydwas administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). Analyses also showed a positive immunological response to the treatment and the clinical course appears promising with all individuals remaining insulin-independent 12 months after treatment.

"These results are very encouraging and the next step is together with collaborators and authorities evaluate the regulatory requirements to get the diabetes vaccine Diamyd approved as a disease-modifying therapy in individuals diagnosed with LADA", says Ulf Hannelius, CEO of Diamyd Medical.

All patients in the trial were followed for twelve months after their first injection. The topline results showed that the safety was good with no treatment-related severe adverse events. The treatment was well tolerated by the trial participants, all of whom completed the study with no drop-outs. The immunological analyses showed a similar response to the treatment as has been shown in previous trials in individuals with recent-onset type 1 diabetes, with a clear GAD-specific immune response evident in both circulating antibodies and cell-based reactions.

The clinical course appears positive with all 14 individuals remaining insulin-independent after 12 months of follow-up. The endogenous insulin production, measured as mixed-meal stimulated C-peptide, declined on average only 10% over 12 months.

"The GADinLADA trial has been successful, and treatment with three intralymphatic injections of Diamyd has been well received by the LADA patients," says PhD Ingrid K Hals, Sponsor's representative of the trial. "We will present the results from this trial at the upcoming international Europen Association for the Study of Diabetes (EASD) conference in Stockholm in September and we look forward to evaluating together with Diamyd Medical the next steps to make this important treatment available for individuals diagnosed with LADA."

Of the 14 LADA patients included in the trial, half carry the HLA haplotype DR3-DQ2 that is associated with a positive clinical response to Diamyd treatment in individuals recently diagnosed with type 1 diabetes. For the 7 individuals carrying HLA DR3-DQ2, endogenous insulin production (stimulated C-peptide) decreased on average by 8 % over the 12 month study period, while in the 7 individuals not carrying HLA DR3-DQ2, it declined by 13 %. GAD-stimulated cell proliferation showed a decrease in proliferation between 5 and 12 months for the HLA-DR3-DQ2 group while a comparable decrease was not observed for the group negative for HLA DR3-DQ2, reflecting the patterns seen in recent-onset type 1 diabetes.

The results will be presented at the upcoming EASD conference to be held in Stockholm on September 19-23, 2022. The accepted abstract is entitled "Early effects of treatment with intralymphatic administration of rhGAD65 in LADA appear similar to those observed in type 1 diabetes", and will be presented as an oral abstract on September 20, 2022, as part of the session "OP 10 Beta cells: protecting what is precious".

About the GADinLADA trialThe main aim of the trial was to evaluate the safety of three intralymphatic injections of Diamyd in patients with LADA (Latent Autoimmune Diabetes in Adults). The patients were recruited in Norway at the Norwegian University of Science and Technology (NTNU), Dept. of Clinical and Molecular Medicine, in Trondheim, in collaboration with St. Olavs Hospital, University Hospital in Trondheim, and in Sweden at the Center for Diabetes, Akademiskt specialistcentrum, an academic specialist unit run in collaboration between Stockholm County's healthcare area, Karolinska Institutet and Karolinska University Hospital. The patients included in the trial were between 30 and 70 years old, diagnosed with LADA within the last 18 months and were not yet on insulin therapy. The Sponsor of the trial has been the Norwegian University of Science and Technology with Ingrid K Hals, PhD, as Sponsor's representative. Diamyd Medical has contributed with study drugs, expertise and some financial support for immunological analyses and determination of HLA haplotypes.

About LADALatent Autoimmune Diabetes in Adults represents close to 10% of patients diagnosed with type 2 diabetes. LADA is characterized by an ongoing autoimmune destruction of the insulin-producing beta cells, a process similar to that of type 1 diabetes, but slower. Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at diagnosis, but for most patients, insulin therapy is required within a few years of diagnosis.

About Diamyd MedicalDiamyd Medical develops precision medicine therapies for Type 1 Diabetes. The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. DIAGNODE-3, a confirmatory Phase III trial is on-going. A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: [emailprotected]

For further information, please contact:Ulf Hannelius, President and CEOPhone: +46 736 35 42 41E-mail: [emailprotected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/diamyd-medical-ab/r/promising-topline-results-for-intralymphatic-diamyd--in-patients-with-lada,c3598517

The following files are available for download:

SOURCE Diamyd Medical AB

Here is the original post:

Promising topline results for intralymphatic Diamyd in patients with LADA - PR Newswire

Lausanne, Switzerland & San Francisco, United States:

New research by scientists at Amazentis and Scripps Research indicates Urolithin A shows promise for improving mobility with beneficial effects on structural damage in joints, published in Aging Cell

Tests in cells from healthy donors and from osteoarthritis (OA) human patients, and in the joints of OA mice, show improvements associated with increased mitochondrial health

Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA). This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005266/en/

(Photo: Amazentis)

This study showed that treatment with Amazentis proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints. And it showed that supplementation with Mitopure for eight weeks protected against osteoarthritis disease progression in an experimental model.

These findings highlight Mitopures benefits for joint and mitochondrial health. Mitopure works by supporting the cells ability to renew their powerplants, the mitochondria, during the aging process. This change is associated with age-related problems in various tissues, including osteoarthritis.

Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations. This new paper extends these benefits to cells in key joints such as the knee. Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.

There are currently no effective solutions to treat osteoarthritis, a condition that is painful and limits the mobility of hundreds of millions of older people around the world. We tested Urolithin A in preclinical models of osteoarthritis and showed it has potential to both reduce inflammation and improve mitochondrial health, suggesting it may be a promising solution to support joint health and quality of life during aging, says Martin Lotz MD, lead author on the paper and Professor of Molecular Medicine at Scripps Research in California, USA.

This study is important and exciting as it shows, for the first time, that Urolithin A can increase mitochondrial health in living joint tissue, says Davide DAmico, first author on the paper and R&D Group Leader with Amazentis. It highlights the important role of mitophagy in maintaining healthy functioning joints throughout life.

In this study, Mitopure showed two key beneficial effects on cartilage cells from both healthy donors and OA patients:

The second part of the study focused on the effect of supplementing Mitopure for 2 months on an experimental pre-clinical model of osteoarthritis. This model mimics the same symptoms experienced by people suffering from osteoarthritis, i.e. progressive cartilage damage, increased pain and inflammation.

"It was great to collaborate with Scripps Research to expand the body of evidence on the health applications of Urolithin A into joint health. Its exciting to see a compound and mechanism of action that is benefiting both muscle and joints. We remain committed to delivering products that are clinically proven to have a meaningful impact on peoples health says Chris Rinsch, CEO and co-founder of Amazentis.

The new results are significant because they add to growing evidence of the benefits of Mitopure on age-related conditions. Recent studies showed that Mitopure can improve mitochondrial health and counteract age-related muscle function decline in both healthy elderly and middle-aged overweight subjects. Together, the latest research supports a combined beneficial action of Urolithin A in both muscle and joints.

Doi: 10.1111/acel.13662

About Amazentis Amazentis is an innovative life sciences company employing todays leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure Urolithin A in top peer reviewed scientific journals including Nature Medicine (doi:10.1038/nm.4132), Nature Metabolism (doi: 10.1038/s42255-019-0073-4), JAMA Network Open (doi:10.1001/jamanetworkopen.2021.44279), Cell Reports Medicine(Doi: 10.1016/j.xcrm.2022.100633) and European Journal of Clinical Nutrition (https://doi.org/10.1038/s41430-021-00950-1). The company has a global strategic partnership with Nestl Health Science to expand the health applications of Mitopure linked to mitochondrial and cellular health. For more information on Amazentis, please visit http://www.amazentis.com.

About Mitopure Mitopure is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit http://www.mitopure.com.

About Timeline Timeline is brought to you by the inventors of Mitopure. This novel, science-first nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit http://www.timelinenutrition.com.

Related Links https://www.amazentis.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005266/en/

Read more:

New Study shows Urolithin A (Mitopure) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis - Business...

Today's early morning highlights from the major news organizations.

KHN:Digital Mental Health Companies Draw Scrutiny And Growing ConcernsWhen Pat Paulsons son told her he was feeling anxious and depressed at college, Paulson went through her Blue Cross Blue Shield provider directory and started calling mental health therapists. No providers in the Wisconsin city where her sons university is located had openings. So she bought a monthly subscription to BetterHelp, a Mountain View, California, company that links people to therapists online. (Meyer, 7/8)

KHN:The Push For Abortion Lawmaking After Dobbs Is Unique, Legal And Political Experts SayThe end of nationwide abortion protections has been met with a wave of calls from lawmakers and governors in at least a dozen states for special legislative sessions that would reshape the state-by-state patchwork of laws that now govern abortion in the U.S. I havent seen so many states focusing their attention so quickly on one issue, said Thad Kousser, a professor who studies state politics. (Zionts, 7/8)

KHN:Vaccine And Testing Delays For Monkeypox Echo Failures In Early Covid ResponseAndy Stone is one of the lucky ones. The New York City resident saw a tweet from a local AIDS activist saying that monkeypox vaccines would be available that day at a clinic in Manhattan. Stone, 35, and his husband booked appointments online right away and got their shots last month. I want to do what I can to protect myself and others, said Stone, a marketing consultant living in Brooklyn, who said his primary care doctor advised him to get the vaccine as soon as possible. (Andrews, 7/8)

KHN:The Search For Scarce Formula Is Worse For Rural Families On WICTwo months after giving birth, Jennifer Magee noticed a change in her babys feeding routine that scared her: She was starting to drink more formula, almost every hour. Increased appetite is normal for growing infants, including Magees daughter, Aubrey. But amid the national formula shortage, Magee, 25, had only one container left, barely enough to last three days. (Saint Louis, 7/8)

KHN:KHNs What The Health?: A Chat With The Surgeon General On Health Worker BurnoutThe pandemic has taken a toll on everyone, but those who work in health care have suffered disproportionately, according to a new report from the office of U.S. Surgeon General Vivek Murthy. And its not just the workers who are at risk. If not addressed, the health worker burnout crisis will make it harder for patients to get care when they need it, cause health costs to rise, hinder our ability to prepare for the next public health emergency, and worsen health disparities, according to the report. (7/7)

AP:Dems Want To Tax High Earners To Protect Medicare SolvencySenate Democrats want to boost taxes on some high earners and use the money to extend the solvency of Medicare, the latest step in the partys election-year attempt to craft a scaled-back version of the economic package that collapsed last year, Democratic aides told The Associated Press. Democrats expect to submit legislative language on their Medicare plan to the Senates parliamentarian in the next few days, the aides said. (Fram, 7/7)

The New York Times:Democrats Propose Raising Taxes On Some High Earners To Bolster MedicareThe proposal is projected to raise $203 billion over a decade by imposing an additional 3.8 percent tax on income earned from owning a piece of what is known as a pass-through business, such as a law firm or medical practice. The money that would be generated by the change is estimated to be enough to extend the solvency of the Medicare trust fund that pays for hospital care currently set to begin running out of money in 2028 until 2031. (Cochrane, Sanger-Katz and Tankersley, 7/7)

Politico:Dems' Climate And Tax Agenda To Consume Congress In JulyNegotiators are still ironing out key details, but Democrats are signaling that as soon as next week they will begin arguing their case to the Senate rules chief on why the package should pass with a simple majority in the chamber. No one is getting their hopes too high in a party still reeling from Manchins rejection of Build Back Better, Democrats previous version of the legislation. (Everett and Levine, 7/7)

The Hill:Newsom Announces California Will Produce Its Own Low Cost InsulinCalifornia Gov. Gavin Newsom (D) announced on Thursday that his state will be producing its own low cost insulin, stating, People should not go into debt to get lifesaving medication. Newsom said that the state budget he recently signed includes $100 million for California to contract and make [its] own insulin at a cheaper price, close to at cost, and to make it available to all. (Breslin, 7/7)

The Hill:GOP Senators Call For Hearings On Bipartisan Insulin Cost BillFive GOP senators are calling on the Senate Finance Committee to hold hearings on bipartisan legislation to lower the cost of insulin. Led by Sens. Pat Toomey (Pa.), and John Barrasso (Wyo.), the Republicans said they were concerned the legislation from Sens. Susan Collins (R-Maine) and Jeanne Shaheen (D-N.H.) will be brought to the Senate floor for a vote without going through the committee first. (Weixel, 7/7)

AP:Facing Pressure, Biden To Sign Order On Abortion AccessPresident Joe Biden will take executive action Friday to protect access to abortion, according to three people familiar with the matter, as he faces mounting pressure from Democrats to be more forceful on the subject after the Supreme Court ended a constitutional right to the procedure two weeks ago. Biden will speak Friday morning on protecting access to reproductive health care services, the sources said. The actions he was expected to outline are intended to try to mitigate some potential penalties women seeking abortion may face after the ruling, but are limited in their ability to safeguard access to abortion nationwide. (Kim and Miller, 7/8)

The Hill:Feinstein Says Shed Vote For Filibuster Carve-Out To Codify Abortion RightsSen. Dianne Feinstein (D-Calif.) on Thursday said she supports the Senate removing the procedural filibuster rule in order to codify abortion rights into law. Feinstein said she certainly would vote to support a carve-out to the filibuster to pass the Womens Health Protection Act and codify federal-level abortion protections. (Dress, 7/7)

AP:Lone Mississippi Abortion Clinic Seeks Legal Path To ReopenAttorneys for Mississippis only abortion clinic filed papers Thursday asking the state Supreme Court to block a new law that bans most abortions and to let the clinic reopen next week. The clinic, Jackson Womens Health Organization, is at the center of the recent U.S. Supreme Court ruling that overturned Roe v. Wade and took away womens constitutional protection for abortion nationwide. (Pettus and Kolpack, 7/7)

Axios:North Dakota's Only Abortion Clinic Sues State Over Trigger BanRed River Womens Clinic, the only remaining abortion provider in North Dakota, is suing state officials over the state's trigger ban, which is set to take effect later this summer. (Gonzalez, 7/7)

AP:Indiana's Abortion Laws May Tighten Before Legislature ActsIndianas abortion laws will likely be tightened even before the Legislature is expected to start debating additional abortion restrictions later this month. Lawyers for the American Civil Liberties Union of Indiana conceded defeat Friday in their fight to block two anti-abortion laws following the U.S. Supreme Courts decision last month to end constitutional protection for abortion. That led the state attorney generals office on Wednesday to ask U.S. District Judge Sarah Evans Barker in Indianapolis to sign off on orders that would lift her injunctions that have prevented enforcement of those laws. (Davies, 7/7)

The New York Times:After Roe, South Carolina Considers More Restrictions On AbortionWith anti-abortion Republicans in firm control of South Carolinas legislature and executive branch, a new proposal offering something closer to an outright ban seems quite likely, although the details have yet to be hammered out. On Thursday, the exploration of a new abortion law began with a meeting of a 14-member, Republican-dominated House committee. But a bill introduced in the House has been left intentionally vague, with just a few lines of text including a statement that state law would be changed so as to prohibit abortions in the state of South Carolina. (Fausset and Sasani, 7/7)

AP:Senate GOP Advances Constitutional Amendment On AbortionRepublican state senators outvoted impassioned Democratic opposition late Thursday to advance a proposal to add language to the Pennsylvania Constitution stating explicitly that the document does not guarantee any rights relating to abortion or public funding of abortions. (Scolforo, 7/7)

USA Today:'DIY Abortion' On TikTok: Experts Urge Americans To Avoid These HerbsThe changing landscape of abortion access across the country has prompted many Americans to turn to the internet for answers, including how to self-manage an unwanted pregnancy at home. Google searches for DIYabortion have skyrocketed since the Supreme Courts decision in June overturning Roe v. Wade, the nearly 50-year landmark ruling that legalized abortion nationwide. (Rodriguez, 7/7)

NBC News:U.S. To Ship 144,000 More Monkeypox Shots And Expand Testing As Cases Top 700The Department of Health and Human Services announced Thursday that it will distribute 144,000 doses of the two-shot Jynneos vaccine, which is approved for monkeypox and smallpox, to cities and states starting Monday. That's on top of 56,000 doses the department made available last week, of which 41,000 have been delivered. (Bendix, 7/8)

CIDRAP:US Monkeypox Cases Top 600 In 34 StatesThe monkeypox virus outbreak is growing in the United States and elsewhere, with the US Centers for Disease Control and Prevention (CDC) now reporting 605 cases in 34 states, the District of Columbia, and Puerto Rico. New York has the most cases, with 122, followed by California with 116 and Florida with 64. (Soucheray, 7/7)

AP:Louisiana Identifies 1st Known Monkeypox Case In A ResidentLouisianas first detected cases of monkeypox have been found in a state resident and a visitor from out of state, the Louisiana Department of Health reported Thursday. There are likely more undiagnosed human cases of monkeypox existing in Louisiana than have been formally tested and identified to date, a news release said. (7/7)

AP:6 Monkeypox Cases Confirmed In OregonHealth officials in Oregon said Thursday they have confirmed six cases of monkeypox in the state. The cases all affecting men include one in Multnomah County; three in Lane County; and two in Washington County, the Oregon Health Authority said in a statement. There have been no deaths. (7/7)

The Boston Globe:10 More Monkeypox Cases Diagnosed In Massachusetts As State Initiates Vaccination ProgramTen more men in Massachusetts have been diagnosed with monkeypox in the past week, bringing the number of cases in the state to 31 since the first infection was announced on May 18, health officials said Thursday, as the state rolled out a vaccination program for those at highest risk. (Fox, 7/7)

The Baltimore Sun:A Baltimore Resident With A Case Of Monkeypox Makes The Case For An Urgent Public Health ResponseAs his trip to Europe in mid-June was winding down, Justin, a 48-year-old Baltimore man, developed a fever and sore throat. His lymph nodes swelled. When I started seeing dots on my body I thought, oh, boy, this isnt anything Ive experienced before, he said. (Cohn, 7/7)

Newsweek:Abe Shinzo Shot Despite Japan Having Incredibly Strict Gun LawsIn 1958, it was written into Japanese law that "no person shall possess a firearm or firearms or a sword or swords,"the opposite of the U.S. Second Amendment's affirmation of the "right of the people to keep and bear arms." Handguns are forbidden, while small-caliber rifles have been illegal to buy, sell or transfer since 1971. The only guns that Japanese citizens can legally buy and use are shotguns and air rifles. To do so involves negotiating a head spinning amount of red tape, requiring attendance at an all-day class, passing a written test and getting at least 95 percent accuracy during a shooting-range test. (Cole, 7/8)

The Washington Post:With Little Outcry, Chicagos Bloody Weekend Eclipsed Highland Park TollNo new counseling resources were announced this week on this citys impoverished South Side, even after a man was shot to death in broad daylight, feet from a playground, days before July Fourth. There are no crowdsourced charity drives raising millions for victims families in Chicago, where the holiday weekend death toll reached at least 10 with 62 injured numbers that exceed the toll from a July Fourth parade shooting in nearby Highland Park, Ill. In that affluent lakeside suburb, the violence was an anomaly. Here, it is a grimly regular occurrence. (Klemko, 7/7)

ABC News:NYPD Says Murders And Shootings Are Down, Despite Recent High-Profile IncidentsThe New York City Police Department said Thursday that murders and shootings are down in the city, despite three people being killed within an hour the night before. In June, murders were down 12% compared to the same period last year and shootings decreased by 13% last month compared to June 2021, the department said. (Grant and Katersky, 7/7)

ABC News:About 300,000 Kids Under 5 Have Gotten At Least 1 Dose Of COVID Vaccine So FarBy the end of Thursday, roughly 300,000 children under the age of 5 years old will have received at least one dose of a COVID-19 vaccine, a senior Biden administration official told ABC News. The 300,000 shots in arms so far for kids under 5 is about 1.5% of the roughly 19.5 million U.S. children 4 years old and younger. (Pezenik, 7/7)

AP:Slow Pace For Youngest Kids Getting COVID Vaccine DosesU.S. officials had long predicted that the pace of vaccinating the youngest kids would be slower than for older groups. They expect most shots to take place at pediatricians offices. ... More than 5 million pediatric doses have been shipped to more than 15,000 locations, the White House said, ready for parents and kids to come in. (Miller and Johnson, 7/7)

The New York Times:What The BA.5 Subvariant Could Mean For The United StatesThe most transmissible variant yet of the coronavirus is threatening a fresh wave of infections in the United States, even among those who have recovered from the virus fairly recently. ... I think theres an underappreciation of what its going to do to the country, and it already is exerting its effect, said Eric Topol, a professor of molecular medicine at Scripps Research, who has written about the subvariant. (Leatherby, 7/7)

San Francisco Chronicle:Whats The Risk Of Getting COVID Outside? Heres Why New Variants May Have Changed The AnswerHealth experts agree that outdoor activities are still much safer than indoors, since viral aerosols dont have a chance to accumulate in the air. But with the most transmissible variants yet, chances are you have less protection in certain situations. Being at parks and outdoor sporting events is still what we should turn to, said Dr. Anne Liu, an infectious disease doctor at Stanford. But if you are in a dense crowd or in an outdoor space that has been modified to look like an indoor space, then the risk becomes higher. (Vaziri, 7/7)

Houston Chronicle:Harris County Surpasses 1 Million COVID Cases Under Worst Surge YetHarris County this week officially surpassed one millionconfirmed COVID-19 cases,according to state health department data, but medical experts saythe true number is likely much higher. The continuing surge of infections has been attributed to BA.5, the newest sub-variant. BA.5 accounts for 53.6% of new cases, making it the dominant COVID strain in the U.S., according to the Centers for Disease Control. (Dozier, 7/7)

AP:COVID-19 Cases Prompt Mask Mandate At Denali National ParkMasks will be required for people using federal buildings or riding buses inside Denali National Park and Preserve because of high COVID-19 levels in the broader community, officials said Thursday. The mask mandate takes effect Friday, a statement from the park said. (7/7)

Los Angeles Times:Physicians Caution Against Working Through COVID-19Physicians caution, however, that rest is an important part of weathering a COVID-19 infection. Plugging away from home is better than putting others at risk of getting infected, but it can still strain the immune system, worsening the toll of a COVID infection, experts say. (Alpert Reyes, 7/7)

The New York Times:The Pandemic Has Eroded Americans Trust In Experts And Elected Leaders Alike, A Survey FindsAs the coronavirus pandemic entered its third year, the American public had lost much of its trust both in public health experts and in government leaders, and was less worried than before about Covid-19, according to a survey conducted in early May and released Thursday by the Pew Research Center. (Chung and Olson, 7/8)

The Atlantic:How Are We Possibly Still Disinfecting Things?Although most people are no longer disinfecting their groceries, signs flaunting cleanliness are still all over the place. Public bathrooms tout regular spray-downs with disinfectant. Elevators advertise self-cleaning buttons. At my local Marshalls, the cashier sanitizes the credit-card reader after every useeven if I use Apple Pay! A recent issue of United Airlines in-flight magazine was treated with an antimicrobial process, according to its cover. Signs lining the queue for a Delta flight in June read, cryptically: certified by lysol pro solutions. (Tayag, 7/7)

The Wall Street Journal:Theranoss Ramesh Sunny Balwani Found Guilty On All 12 Fraud CountsA federal jury convicted Ramesh Sunny Balwani, the former top lieutenant to Theranos Inc. founder Elizabeth Holmes, on all 12 charges that he helped perpetuate a yearslong fraud scheme at the blood-testing startup. The verdict is the second conviction against Theranos leadership and comes six months after a jury found Ms. Holmes guilty of fraud; it secures another major victory for the U.S. government, which brought the case against the pair in 2018. (Somerville and Bobrowsky, 7/7)

Stat:Drug Companies Will Have To Start Refunding Medicare For Certain DrugsStarting next year,pharmaceutical companies will have to repay Medicare for any unused amount of drugs that come in single-dose vials. On Thursday Medicare implemented this new provision as part of its broader annual rule that updates physician payments for 2023. (Herman, 7/7)

AP:Whistleblower Physician Reinstated At California VA HospitalA whistleblower physician who was forced into retirement after raising concerns about anesthesia staffing practices during surgeries at a Los Angeles Veterans Affairs hospital has gotten his old job back, federal officials said Thursday. (7/7)

AP:Northern West Virginia Hospital Settles With Feds For $1.5MA hospital in West Virginias Northern Panhandle has agreed to pay $1.5 million to the federal government to settle allegations that the medical center provided financial incentives to physicians for referring Medicare patients there, U.S. Justice Department officials said Thursday. (7/7)

Health News Florida:A Florida Medical Malpractice Case Is Under The Microscope Of Hospital And Doctor GroupsState and national groups representing hospitals and doctors are trying to help sway the Florida Supreme Court in a dispute about whether a medical malpractice lawsuit should have been allowed to move forward. (Saunders, 7/7)

AP:NC Governor Signs Bills Addressing Sexual Assaults, AlcoholNorth Carolina Gov. Roy Cooper signed 11 bills on his desk into law Thursday, including legislation that addresses sexual assault, domestic violence and alcohol sales. ... One signed measure makes clear that hospitals or medical offices cant attempt to bill victims of sexual assault or their insurance companies for forensic medical examinations, leaving it to a special state fund thats already been in place to cover the payment. (Robertson, 7/7)

AP:Fentanyl-Driven Overdoses Jump, Officials Urge NaloxoneAn Oregon Health Authority analysis released Thursday has found that drug overdose deaths in Oregon more than doubled between 2019 and 2021, driven largely by misuse of the powerful synthetic opioid fentanyl. (7/8)

CIDRAP:CDC Reports 12 More Unexplained Hepatitis Cases In Kids, 332 TotalIn a weekly update, the US Centers for Disease Control and Prevention (CDC) yesterday reported 12 more unexplained pediatric hepatitis cases in children, raising the national total to 332. The number of affected states held steady, at 42. (7/7)

The Boston Globe:Four Young Adults Sickened After Cohasset Swim Center Opens Prematurely, Town SaysFour young adults participating in a swim practice were sickened at the Cohasset Swim Center on Wednesday after the facility opened prematurely and a broken pipe caused a leak in its largest pool, town officials said. The center, which is not owned or operated by the town, opened to the public without its finalized building permit or pool health inspection permit, according to a statement Thursday from the office of Cohasset Town Manager Christopher G. Senior. (Fox, 7/7)

WUSF Public Media:Contaminated Oysters Found As Far North As Tampa Bay Could Pose Health RisksWith a new state law addressing the clean-up of chemical compounds that have been widely used by industries, a Florida International University study says the substances have been found in oysters in Biscayne Bay, the Marco Island area and Tampa Bay. (7/7)

Albany Herald:CIT Bracelets Help Ease Encounters Between Police, Mental Health SufferersAs a fashion statement theyre not much. But these rubber bracelets could make a big difference with police officers interacting with individuals suffering from mental illness and alter the results of an encounter from a trip to jail to referral to treatment. ... The bracelets, which say CIT (Critical Intervention Training) on one side and Mental Health Alert on the other, can let police know how to better handle a situation when they encounter someone who is wearing one. (Mauldin, 7/6)

Axios:Race May Factor Into Leukemia Survival, Study SuggestsYounger Black leukemia patients were likelier to die early or not go into complete remission than their white peers when receiving the same intensive treatment, according to a new study in Blood Advances. (Dreher, 7/7)

NPR:Scientists Look To People With Down Syndrome To Test Alzheimer's DrugsPeople with Down syndrome are highly sought after for Alzheimer's research studies because many develop the disease in their 40s and 50s, and most will get it if they live long enough. The elevated risk for Alzheimer's comes from the extra copy of chromosome 21 carried by people with Down syndrome. (Hamilton, 7/7)

NPR:HIV Patients Who Get Leishmaniasis Face A Tough Road. But Now There's New Hope"If you don't get the treatment, you're usually going to die from this," says Dr. Fabiana Alves, director of the leishmaniasis cluster at the Drugs for Neglected Diseases Initiative. VL is even more devastating for a patient whose immune system has been compromised by HIV, simply because the existing VL treatments don't work as well. And in parts of the world where VL is rampant, like eastern Africa and Southeast Asia, a significant percentage of patients are HIV positive. (Barnhart, 7/7)

USA Today:Is 'Hangry' Real? New Study Says You Do Get Angry When HungryIf you are someone whogets angry if youhaven't eaten, also known as "hangry," a new study says you aren't being irrational.The findings, published in the peer-reviewed journalPlos One on Wednesday, come from one of the first studies to examine the relationship of hunger and anger,Viren Swami, lead author and social psychology professor at Anglia Ruskin University in the U.K., told USA TODAY via email. (Mendoza, 7/7)

Read this article:

First Edition: July 8, 2022 - Kaiser Health News

Wilmington, Delaware, United States, Transparency Market Research Inc.: Eye-related disorders are expanding at an accelerated pace across the globe. One of the most common disorders of the eyes is dry eye disease. The growing geriatric population and the increasing screen time among individuals have resulted in the rising cases of dry eye diseases. According to numerous studies, the incidence of dry eye diseases is between the ranges of 8 percent to 34 percent. Hence, these factors have influenced the growth structure of the dry eye disease market considerably and will continue to influence during the forecast period of 2017-2025.

When an individual suffers from dry eye disease, his/her eyes do not produce enough tears. Dry eye also occurs when one is not able to maintain a normal layer of tears for coating the eyes. The common symptoms of dry eye disease are redness, stringy mucus, blurry vision, pain, difficulty reading, or not able to sit before the computer for long hours, etc. Dry eye disease is of two types: aqueous deficiency dry eye disease and evaporative dry eye disease.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26096

The prominent risk factors for eye diseases are diabetes, refractive surgeries, aging, consumption of certain medications, etc. Anti-inflammatory drugs, cyclosporine, artificial tears, lifitegrast, secretagogue, punctal plugs, and others are some vital treatment types for eye diseases.

The players indulge in research and development activities for expanding the growth landscape of the dry eye disease market. The players invest in these activities to find new treatments for dry eye diseases. These activities help in strengthening the revenue cycle of the global market, eventually increasing the growth rate. Mergers, acquisitions, joint ventures, and partnerships also form an important part of the dry eye disease market growth structure. These collaborations assure expansion of the treatment types in other regions and significantly impact the growth trajectory.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26096

According to the TMR experts, the market for dry eye disease is prognosticated to expand at 4.5 percent CAGR during the forecast period of 2017-2025. In the context of valuation, the plasma protein therapeutics market is estimated to reach a valuation of US$ 7,780 mn by 2025 and was valued at US$ 5045.2 mn in 2016.

Anti-Inflammatory Drugs to Reign Supreme in Terms of Demand

The use of anti-inflammatory drugs for treating dry eye diseases has increased exponentially over the years. Research activities revolving around anti-inflammatory drugs are increasing extensively, ultimately leading to an increase in the development of new drugs. These factors will influence the growth of the dry eye disease market to a considerable extent. The anti-inflammatory drugs segment is expected to dominate in terms of revenue and demand, whereas the artificial tears segment may emerge as the second-largest growth-contributing segment.

Request for Analysis of COVID19 Impact on Dry Eye Disease Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=26096

Growing Awareness about Various Treatment Types to Increase Growth Prospects Considerably

Government and non-government initiatives are encouraging many individuals to diagnose and get treated for dry eye diseases. This factor will have a great impact on the growth of the dry eye disease market. Further, many companies in the dry eye disease market promote their products through effective strategies, ultimately contributing to the growth trajectory.

Accelerated FDA Approvals to Boost Growth of North Americas Dry Eye Disease Market

The approvals for new dry eye disease treatment drugs at a rapid pace will bring immense growth prospects for the dry eye disease market in North America. The Food and Drug Administration (FDA) is trying to speed up the approval process to provide good and effective dry eye disease treatment options to the citizens. Hence, this factor will help North Americas dry eye disease market to gain a larger growth share.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=26096

Some well-entrenched players in the dry eye disease market are Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., Otsuka Pharmaceutical Co., Ltd., TRB Chemedica International SA, Novartis AG, Johnson & Johnson, and Sentiss Pharma Pvt. Ltd.

More Trending Reports by Transparency Market Research

Gene Therapy Market: Gene Therapy Market (Product: Instruments, Media, Sera, and Reagents; and End-user: Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Pulmonary Arterial Hypertension Market: Pulmonary Arterial Hypertension (PAH) Market (Pipeline Analysis: Early-stage Drug Candidates [Phase I & Phase II] and Late-stage Drug Candidates; and Drug Class: Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists [ERAs], Phosphodiesterase-5 [PDE-5] Inhibitors, and Soluble Guanylate Cyclase [sGC] Stimulators) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Forensic Technologies Market: Forensic Technologies Market (Service: DNA Profiling; Chemical Analysis; Biometric/Fingerprint Analysis, Firearm Analysis, and Others; and Location: Laboratory Forensics [LIMS] and Portable Forensics [FaaS]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Microbiology Culture Market: Microbiology Culture Market (Type: Liquid Media and Plate Media; Culture Type: Bacterial Culture, Eukaryotic Culture, and Virus and Phage Culture; Media Type: Simple Media, Complex Media, Synthetic Media, Special Media, and Others; and Application: Food & Water Testing, Bioenergy & Agricultural Research, Cosmetic Industry, Pharmaceutical Industry, and Others) - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Nanomedicine Market: Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others [Dental, Orthopedic, Urology, and Ophthalmic]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Smart Medical Devices Market: Smart Medical Devices Market (Product Type: Diagnostic & Monitoring Devices, Therapeutic Devices, Injury Prevention & Rehabilitation Devices, and Others; Modality: Portable, Wearable, and Others; and End-user: Hospitals, Clinics, Home Care Settings, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Bioinformatics Market: Bioinformatics Market (Platforms, Tools, and Services: Platforms, Tools, and Services; and Application: Preventive Medicine, Molecular Medicine, Gene Therapy, Drug Development, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Taurine Market: Taurine Market (Type: Food Grade and Pharmaceutical Grade; Application: Health Care Products, Pet Food, Beverage, and Others; and Form: Tablets/Capsules, Liquid-based Serum, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and business consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Visit link:

Dry Eye Disease Market: Increasing Awareness and the Booming Geriatric Population to Accelerate the Market Growth - BioSpace

* WHO provides technical support to the study on investigating seroprevalence of SARS-CoV-2 and dengue infections in Sri Lankan childrenFri, Jul 8, 2022, 12:23 pm SL Time, ColomboPage News Desk, Sri Lanka.

July 08, Colombo: Sri Lanka too experienced a rapid rise in number of cases and deaths, with the community spread of the Delta variant of the SARS-CoV -2 virus. However, deaths were predominantly seen among adults, with children rarely developing severe disease, as observed in other countries.

Sri Lanka experienced two massive COVID-19 outbreaks due to the Alpha and Delta variants of the SARS-CoV -2 virus, resulting in a large number of individuals being infected in the community. It was estimated that surveillance of SARS-CoV-2 with the Real-time polymerase chain reaction (RT-PCR) testing alone may underestimate the true prevalence of the disease by tenfold. Therefore, conducting a seroprevalence study remained an option for Sri Lanka to determine prevalence of SARS CoV-2 specific antibodies due to infection or vaccines in the country.

Seroprevalence studies help understand the true extent of an outbreak and provide valuable insights in to efforts that help project the trend of future outbreaks, and their transmission dynamics. However, in Sri Lanka, a majority of infections was reported in adults, most of whom experienced more severe and symptomatic infections. On the other hand, true infection rates among children in the country were not clearly known. One of the reasons for this could be limited PCR testing in children, largely because they do not show symptoms following infection with SARS-CoV-2 virus. Also, infection rates could be very different across districts, based on the intensity of transmission reported in different geographical regions.

Considering the above, the Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura and the Ministry of Health supported by WHO Country Office for Sri Lanka planned a study on seroprevalence of SARS-CoV-2 infections and dengue infections in Sri Lankan children.

In order to submit the study protocol to WHOs Ethical Review Committee, a joint review of study protocols was undertaken by the Unity trial desk of WHO Headquarters, the SEA Regional Office and the WHO country office for Sri Lanka. After revising the study protocol based on WHO recommendations, investigators submitted the finalized protocol to the Regional Review Committee.

The proposed study will help Sri Lanka determine the proportion of children who have been infected with COVID-19 and also with dengue, by studying the presence of antibodies to these viruses in children of different age groups. Additionally, it will determine genetic associations that predispose children to severe disease of dengue. Further, the study will provide information that will help understand how COVID-19 and dengue have spread geographically in the Sri Lankan population.

The seroprevalence in this study will be determined by biological assays, which are both qualitative and quantitative (ELISA, Luminex). The patient data will be collected on clinical features, clinical disease severity and complications.

The findings of this investigation will be used to inform public health response to COVID-19. Specifically, it can provide estimates of otherwise unrecognized SARS-CoV-2 infection in the population, as well as likely susceptibility of the population to further epidemic peaks. The findings may also supplement other supportive evidence used to inform decision-making about vaccine prioritization for target groups, based on demonstrated susceptibility by age groups.

Read the original here:

Sri Lanka : WHO provides technical support to the study on investigating seroprevalence of SARS-CoV-2 and dengue infections in Sri Lankan children -...

The 2021 H.L. Holmes Award was presented to Dr. Khalid Al-Zahrani for his novel advancements in breast cancer research. In developing a never-before-seen method, he is able to screen for specific cancer driving genes and has validated his research with promising results.

Over two years, the $180,000 award will support Dr. Al-Zahrani in the development of a gene system to identify the cause of basal-like breast cancer (BLBC). As BLBC disproportionally affects younger, premenopausal women and has a relatively poor clinical prognosis, his research will expand our knowledge of this aggressive cancer subtype which could greatly improve existing treatment methods.

Dr. Al-Zahrani will continue to work with Mount Sinai's Lunenfeld-Tanenbaum Research Institute in Toronto where he has been a post-doctoral research fellow since 2019 in Dr. Daniel Schramek's group, a world-renowned expert in genetic models of cancer. Dr. Al-Zahrani completed his Ph.D. (Philosophy, Cellular and Molecular Medicine) and B.Sc. (Specialization in Biochemistry) at the University of Ottawa and has published over a dozen articles in scientific and medical journals. As a Canadian with roots in Scotland and Saudi Arabia, Dr. Al-Zahrani is excited to develop new medicine that will help people worldwide.

Already, Dr. Al-Zahrani is exploring the uncharted field of BLBC copy number alterations with the development of a novel in vivo CRISPR technology. BLBC copy number alterations are parts of the DNA that are gained or lost that cause tumors to develop from normal cells, and in vivo refers to experiments in whole, living organisms. Using the CRISPR system, researchers can edit genes by activating or deactivating specific parts of genetic code, which allows for precise manipulation of DNA. Dr. Al-Zahrani is a pioneer in the field of BLBC genetics as he aims to understand the underlying mechanisms that drive cancer cells. His findings may uncover new approaches in the way we provide treatment.

Over two years, Dr. Al-Zahrani generated 14 different gene targeting systems in hopes of finding an all-in-one solution to target and screen specific cancer cells. He developed a technology termed KOALA (Knock-Out and Activation Linked Assay) which, when paired with CRISPR, can pick out certain parts of genetic code and trigger precise activation or deactivation. Overcoming numerous roadblocks, he finally achieved a system sufficient for use in mouse specimens. His method will allow for screening of specific BLBC genes and may ultimately identify parts of genetic code that trigger tumor growth. Importantly, KOALA allows for the rapid screening of thousands of cancer-causing genes in a single experiment, whereas conventional techniques screen a single potential cancer-causing gene at a time. The efficiency of his system is validated by discovering several new potential targets for treating BLBC. This is a pivotal step in understanding breast cancer as it greatly improves upon existing methodologies by saving both time and money in the identification of important cancer-driving genes. In combination with conventional tumor-suppressing gene therapy, identification of specific cancer-causing genes allows for highly targeted therapeutic approaches.

While mouse models are suitable for initial experiments, Dr. Al-Zahrani will carefully evaluate further findings in human patient samples. His innovative progress has the potential to uncover new effective cancer treatments and improve the clinical prognosis of basal-like breast cancer.

Original post:

The NRC HL Holmes Award supports the development of technology to target and treat basal-like breast cancer - National Research Council Canada -...

Wilmington, Delaware, United States, Transparency Market Research Inc.: Transparency Market Research (TMR) has published a new report titled, Blood Group Typing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018 to 2026. According to the report, the global blood group typing market was valued at US$ 1,500.0 Mn in 2017 and is projected to reach US$ 3,556.0 Mn by 2026, expanding at a high CAGR of 10.3% from 2018 to 2026. Increase in blood transfusion rate across the world is anticipated to fuel the global blood group typing market during the forecast period.

North America and Europe are expected to dominate the global market during the forecast period. The market in these regions is primarily driven by the increase in government initiatives and a highly structured health care industry. The market in Europe is projected to expand at a high growth rate of 10.1% from 2018 to 2026. The market in Asia Pacific is expected to expand at a rapid pace during the forecast period. The market in Asia Pacific is anticipated to expand at a high CAGR of 10.7% from 2018 to 2026. The blood group typing market in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=48627

Increase in preference for PCR-based technique to boost market

In terms of technique, the PCR-based segment is projected to account for a dominant share of the global blood group typing market during the forecast period. The segment is anticipated to expand at a CAGR of 10.6% from 2018 to 2026. Dominance of the segment is attributed to the increasing preference for PCR-based technique because of rising incidence of major chronic diseases such as aplastic anemia, sickle cell anemia, leukemia, and traumatic injuries, resulting increase in blood transfusion rate in countries across the globe.

Additionally, increasing the usage of PCR-based technique in the detection of rare type of blood group is a key factor that is expected to fuel the segment. The microarray-based segment held a major share of the market, following the PCR-based segment, due to increasing awareness about this technique. Assay-based technique and massively parallel technique segments accounted for around 30.0% share of the global blood group typing market, in terms of revenue, in 2017.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=48627

Consumables segment dominates the market

The report offers detailed segmentation of the global blood group typing market based on product, technique, test, and end-user. In terms of product, the market has been classified into instrument (automated, semi-automated, and manual), consumables (reagent, test kits, antisera, others), and services. The consumables segment is estimated to hold a leading share of the global market during the forecast period. Higher share held by the segment is attributed to the constant development of new molecular diagnostic test kits and reagents, which reduces the turnaround time required for results, and increase in number of blood transfusions, globally, every year are key factors fueling the consumables segment.

Antibody screening test & ABO blood test: Top two test employed for blood group typing

In terms of test, the antibody screening test segment is projected to hold a dominant share of global blood group typing market by the end of the forecast period. The segment is likely to expand at a CAGR more than 10.0% between 2018 and 2026. Major factor responsible for the dominance of this segment is the rise in incidence of transfusion transmitted infections (TTIs), especially in lower-middle income and low-income countries. The ABO blood test segment held a major share, following the antibody screening test, due to increasing utilization of this test for blood grouping. HLA typing and antigen segments accounted for around 30.0% share of the global blood group typing market, in terms of revenue, in 2017.

Request for Analysis of COVID-19 Impact of Blood Group Typing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=48627

Hospital segment to expand at significant CAGR

Based on end-user, the hospital segment accounted for a leading share of the global blood group typing market in 2017. It is projected to gain market share by the end of 2026. The segment is anticipated to expand at a CAGR of 10% during the forecast period due to the large patient population undergoing surgical procedures in hospitals requiring blood transfusion, and increasing emphasis on blood grouping and patient testing. Clinical laboratories was a prominent segment, following the hospital segment, of the market in 2017. This is due to the rise in number of clinical laboratories for blood grouping and screening. This, in turn, is likely to drive the clinical laboratories segment during the forecast period.

North America to be highly lucrative market for blood group typing market

The blood group typing market in North America is driven by high percentage of active and voluntary blood donors in the U.S. and Canada, increasing number of blood transfusions per year in the region, and various blood transfusion policies being implemented regarding safety and testing of blood for infectious diseases. This, in turn, is further boosting the demand for blood grouping instruments and kits and reagents in North America. Moreover, a large number of players in the U.S. are focusing on R&D in order to introduce new products. The U.S. is an early adopter of innovative products, as most pharmaceutical products are first launched in the country. This is likely to boost the market in the country in the near future.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=48627

Trend of strategic alliance with local companies to strengthen distribution network and expand geographic presence

The global blood group typing market is fragmented, owing to the presence of several small- and large-scale companies. However, the market is dominated by a few major players with strong global presence. The report provides profiles of leading players operating in the global blood group typing market. Key players in the market include Grifols, S. A., Bio-Rad Laboratories, Inc., Merck KGaA, Ortho Clinical Diagnostics, QUOTIENT LIMITED, BAG Health Care GmbH, Immucor, Inc., Beckman Coulter, Inc. (Danaher Corporation), Agena Bioscience, Inc., Rapid Labs Ltd, and Novacyt Group.

More Trending Reports by Transparency Market Research

Forensic Technologies Market: Forensic Technologies Market (Service: DNA Profiling [PCR, Y-STR, RFLP, Mitochondrial DNA, and Others]; Chemical Analysis [Mass Spectrometry, Chromatography, Spectroscopy, and Others]; Biometric/Fingerprint Analysis, Firearm Analysis, and Others; and Location: Laboratory Forensics [LIMS] and Portable Forensics [FaaS]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Microbiology Culture Market: Microbiology Culture Market (Type: Liquid Media and Plate Media; Culture Type: Bacterial Culture, Eukaryotic Culture, and Virus and Phage Culture; Media Type: Simple Media, Complex Media, Synthetic Media, Special Media, and Others; and Application: Food & Water Testing, Bioenergy & Agricultural Research, Cosmetic Industry, Pharmaceutical Industry, and Others) - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Nanomedicine Market: Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others [Dental, Orthopedic, Urology, and Ophthalmic]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Smart Medical Devices Market: Smart Medical Devices Market (Product Type: Diagnostic & Monitoring Devices, Therapeutic Devices, Injury Prevention & Rehabilitation Devices, and Others; Modality: Portable, Wearable, and Others; and End-user: Hospitals, Clinics, Home Care Settings, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Bioinformatics Market: Bioinformatics Market (Platforms, Tools, and Services: Platforms, Tools, and Services; and Application: Preventive Medicine, Molecular Medicine, Gene Therapy, Drug Development, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Taurine Market: Taurine Market (Type: Food Grade and Pharmaceutical Grade; Application: Health Care Products, Pet Food, Beverage, and Others; and Form: Tablets/Capsules, Liquid-based Serum, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Telehealth Market: Telehealth Market (Component: Hardware, Software, and Services; Application: Radiology, Cardiology, Urgent Care, Remote ICU, Psychiatry, Dermatology, and Others; and End-user: Payers, Providers, Patients, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Medical Device Technologies Market: Medical Device Technologies Market (Device Type: Cardiology Devices, Diagnostic Imaging Devices, Orthopedic Devices, Ophthalmology Devices, Endoscopy Devices, Diabetes Care Devices, Wound Management Devices, Kidney/Dialysis Devices, Anesthesia & Respiratory Care Devices, and Others; and End-user: Academics & Research, Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

View original post here:

Blood Group Typing Market: Increase in Blood Transfusion Rate Across the World to Drive the Market - BioSpace

Amaia Lujambio Goizueta, PhD, discusses mutations commonly seen in hepatocellular carcinoma, and the targeted therapies available for these tumors.

Amaia Lujambio Goizueta, PhD, an assistant professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, discusses mutations commonly seen in hepatocellular carcinoma (HCC), and the targeted therapies available for these tumors.

0:08 | Every tumor is very diverse in every tumor type, but HCC is in particular very diverse if we compare it to other tumor types. That means that tumors from different patients have very different mutations and very different combinations of mutations.

0:28 | So, the gene that is most frequently mutated is the promoter of a telomerase, which confers the cancer cells with basically unlimited replication potential. And then there are other genes such as p53, and beta catenin that are also frequently mutated. However, the way these mutations are mutated, they are not mutated together. They are mutated in different patients. So, that makes it more difficult to treat because right now, there are not selective therapies for HCC patients, which means that basically, all the patients receive the same treatment more or less. There are different therapies but there is not a way of selecting the best therapy for each patient.

Go here to see the original:

Understanding the Molecular Diverse Makeup of Hepatocellular Carcinom - Targeted Oncology